Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $7.7 million.

  • Anika Therapeutics' Capital Expenditures rose 55.18% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 9.46%. This contributed to the annual value of $7.7 million for FY2024, which is 42.51% up from last year.
  • Latest data reveals that Anika Therapeutics reported Capital Expenditures of $7.7 million as of FY2024, which was up 42.51% from $5.4 million recorded in FY2023.
  • Anika Therapeutics' 5-year Capital Expenditures high stood at $7.7 million for FY2024, and its period low was $1.6 million during FY2020.
  • Over the past 3 years, Anika Therapeutics' median Capital Expenditures value was $7.5 million (recorded in 2022), while the average stood at $6.9 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 42.41% in 2020, then soared by 215.91% in 2021.
  • Yearly analysis of 5 years shows Anika Therapeutics' Capital Expenditures stood at $1.6 million in 2020, then soared by 215.91% to $5.1 million in 2021, then surged by 45.56% to $7.5 million in 2022, then declined by 27.50% to $5.4 million in 2023, then surged by 42.51% to $7.7 million in 2024.